Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)

Authors: Rachel E. Reingold, MD, Rose Parisi, MD, MBA, Guilherme Harada, MD, Andrea P. Moy, MD, George Dranitsaris, PhD, Jasmine H. Francis, MD, Julia Canestraro, OD, FAAO, Julia A. Lester, MPH, Lauren A. Kaplanis, RN, Dazhi Liu, PharmD, BCOP, Mario E. Lacouture, MD, Alexander Drilon, MD

Source: JTO Clinical and Research Reports, Vol 6, Iss 3, Pp 100792- (2025)

Subject Terms: Selpercatinib, Mucocutaneous adverse event, RET fusion, RET mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364325000086; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/86fff4dcdf624235bbc62f09b66ba6e9